TScan Therapeutics, Inc. (TCRX): Cash & Equivalents
$152.41M
As of 2025-12-31
$100.16M
As of 2026-06-30
+8.3%
3-year compound annual growth
+34.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $152.41M | -14.7% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $178.69M | +34.0% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $133.36M | +11.1% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $120.03M | -25.6% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $161.41M | +363.9% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $34.79M | n/a | 2022-03-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $84.02M | -32.4% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
Compare TCRX, ACOG, TSHA, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗